6/28/23, 1:15 AM DECLARE-TIMI 58 (post-hoc analysis) Pathway Feedback Search Clinical Topics Home Studies DECLARE TIMI 58 (post-hoc analysis) DECLARE TIMI 58 (post-hoc analysis) Disease Diabetes mellitus type 2 Trial question What is the effect of dapagliflozin on hospitalizations in adults with T2DM? Study design Multi-center Double blinded RCT Population Characteristics of study participants 37.0% female N = 17160 63.0% male 17160 patients (6422 female, 10738 male) Inclusion criteria: adults 40 years with T2DM and either risk factors for or established ASCVD Key exclusion criteria: diagnosis of T1DM mellitus; chronic cystitis; recurrent UTIs; pregnancy Interventions N=8582 dapagliflozin (at an oral dose of 10 mg once daily) N=8578 placebo (matching placebo once daily) Primary outcome First non-elective hospitalization for any cause 35.4 % 35.4 32.4 https://web.pathway.md/studies/recvVphFoWgv4nfHo 1/2 6/28/23, 1:15 AM DECLARE-TIMI 58 (post-hoc analysis) Pathway 26.5 % 17.7 % 8.8 % Borderline significant decrease 0.0 % Dapagliflozin Placebo Borderline significant decrease in first non-elective hospitalization for any cause (32.4% vs. 35.4%; HR 0.89, 95% CI 0.85 to 0.94) Conclusion In adults 40 years with T2DM and either risk factors for or established ASCVD, dapagliflozin was superior to placebo with respect to first non-elective hospitalization for any cause. Reference Meir Schechter, Stephen D Wiviott, Itamar Raz et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023 Apr;11(4):233-241. Open reference URL https://web.pathway.md/studies/recvVphFoWgv4nfHo 2/2